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References 6 Table  7 S1. Parameters and prior distributions 7 The model estimates the number of MSM diagnosed each year (D), the number who remain undiagnosed (E), and the annual incidence rate (h). Notably, the population size of the Danish MSM community is not needed in the model to estimate incidence. The model is developed by fitting the estimated diagnosis rates, which are stratified based on CD4 cell levels, to the known number of diagnoses (i.e., to the DHCS data in figure 2A ).
In the model both diagnosed and undiagnosed men MSM are in one of four stages stratified by CD4 
where h t is the expected number of newly infected MSM entering stage 1 at time t, N is the number of discrete-time intervals (where each time interval is a year) and p t,j,k is the one-step probability an individual in stage j moves to stage k during (t,t+1). For stage 4, p t,j,k is the one-step probability that an individual dies during (t,t+1). p t,j,k is calculated from:
where
is the probability that an individual in stage j is diagnosed during the interval (t, t+1) (i.e., the stage-specific diagnosis probability) and δ t,j is the per capita diagnosis rate in stage j. The per capita disease progression rate from stage j to k is represented by q j .
The expected number of MSM diagnosed (D t+1 ) during the time interval (t,t+1) is calculated from:
The proportion of the newly diagnosed MSM who are from stage k during the time interval (t,t+1) is calculated from:
B. Parameter estimates
The per capita disease progression rate from each of the first three stages of the model, as well as the per capita death rate from the fourth stage (q j ), were parameterized using estimates from the literature. 3 These rates are: 0·2 per year for stage 1, 0·36 per year for stage 2, 0·44 per year for stage 3, and 2 per year for stage 4. The median time from infection to death, if untreated, is 10·5 years. We examined the effect of variation in the disease progression rates, and found that variation (within biologically plausible estimates) had relatively little effect on our incidence estimates. Importantly, this showed that variation in the disease progression rates did not affect our main result; specifically, that incidence decreased between 1996 and 2013 as the coverage of treatment increased.
The remaining parameters were estimated using a Bayesian framework, as in Sweeting et al. 1 The incidence rate (h t ) (shown in Equation 1) was modeled as a Poisson process. It was simulated using an autoregressive model on the log-scale to ensure it changed smoothly over time; we used a random walk.
Similar autoregressive models were used to simulate the time-varying diagnosis probabilities (d t,j ) for each CD4 stage. The prior distributions of these parameters are given in Table S1 ; incidence is shown in terms of log incidence (log(h t )=γ t ). The hyper-parameter values were chosen heuristically to ensure suitable volatility in the random walk processes for incidence and the diagnosis probabilities. The distributions for the priors for the incidence and diagnosis probabilities were informed by epidemiological and clinical expertise. We included constraints, for the diagnosis probabilities, to ensure that the posterior estimates were bounded between zero and one.
We used 20,000 Markov Chain-Monte Carlo (MCMC) samples to simulate the back-calculation model,
with an initial burn-in of 5,000 simulations. MATLAB was used for implementation. 4 During the simulations we updated the parameter estimates for the incidence rate, and the stage-specific diagnosis probabilities, by using the diagnosis data from the DHCS and the likelihood function defined by Birrell et al. 2 Median values and Bayesian Credible Intervals (BCIs) for the models' estimates were calculated, and then weighted using the likelihood function. Posterior estimates for the four CD4-cell stratified diagnosis probabilities (median and 95% BCIs) were also calculated. Convergence was assessed by visual inspection of the trace plots.
C. Goodness-of-fit-of the back-calculation model
Goodness 
Additional results:
Our estimates, calculated from the back-calculation model, of the annual diagnosis probability for an MSM in one of the four CD4-stratified stages of infection are shown in figure S2.
Our estimates for the percentage of undiagnosed HIV-infected MSM, calculated from the back-calculation model, are shown in figure S3. 
